[HTML][HTML] The role of immune cells in chronic HBV infection
HJ Li, NC Zhai, HX Song, Y Yang, A Cui… - Journal of clinical and …, 2015 - ncbi.nlm.nih.gov
Hepatitis B virus (HBV) infection is a major cause of chronic liver diseases that may progress
to liver cirrhosis and hepatocellular carcinoma. Host immune responses are important …
to liver cirrhosis and hepatocellular carcinoma. Host immune responses are important …
Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the “magic bullet” to kill cccDNA
E Zhang, A Kosinska, M Lu, H Yan, M Roggendorf - Antiviral research, 2015 - Elsevier
Chronic hepatitis B (CHB) is currently treated with IFN-α and nucleos (t) ide analogues,
which have many clinical benefits, but there is no ultimate cure. The major problem consists …
which have many clinical benefits, but there is no ultimate cure. The major problem consists …
Type 1 innate lymphoid cells contribute to the pathogenesis of chronic hepatitis B
Z Yang, T Tang, X Wei, S Yang, Z Tian - Innate immunity, 2015 - journals.sagepub.com
Innate lymphoid cells (ILCs) function in producing effector cytokines in response to
pathogenic infections. However, the roles and related mechanisms of the ILC …
pathogenic infections. However, the roles and related mechanisms of the ILC …
Decreased Siglec-9 expression on natural killer cell subset associated with persistent HBV replication
D Zhao, X Jiang, Y Xu, H Yang, D Gao, X Li… - Frontiers in …, 2018 - frontiersin.org
Siglec-9 is an MHC-independent inhibitory receptor selectively expressed on CD56dim NK
cells. Its role in infection diseases has not been investigated yet. Here, we studied the …
cells. Its role in infection diseases has not been investigated yet. Here, we studied the …
[HTML][HTML] Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6
YE Lee, GY Go, EY Koh, HN Yoon, M Seo… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME)
contribute to an impaired functionality of natural killer (NK) cells that have emerged as a …
contribute to an impaired functionality of natural killer (NK) cells that have emerged as a …
The role of innate lymphoid cells in immune-mediated liver diseases
M Liu, C Zhang - Frontiers in Immunology, 2017 - frontiersin.org
Innate lymphoid cells (ILCs) are a recently identified group of innate immune cells lacking
antigen-specific receptors that can mediate immune responses and regulate tissue …
antigen-specific receptors that can mediate immune responses and regulate tissue …
Integrated analysis of single-cell and bulk RNA-sequencing reveals tumor heterogeneity and a signature based on NK cell marker genes for predicting prognosis in …
S Li, H Du, D Gan, X Li, X Zao, Y Ye - Frontiers in Pharmacology, 2023 - frontiersin.org
Background: Natural killer (NK) cells are a type of innate immune cell that recognize and
eliminate tumor cells and infected cells, without prior sensitization or activation. Herein, we …
eliminate tumor cells and infected cells, without prior sensitization or activation. Herein, we …
Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression …
Z Tian, B Hong, J Chen, Z Tang - Frontiers in oncology, 2022 - frontiersin.org
Background Radiofrequency ablation (RFA) destroys tumors through hyperthermic injury,
which induces the release of immunogenic intracellular substrates and damages associated …
which induces the release of immunogenic intracellular substrates and damages associated …
Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades
CL Han, YC Yan, LJ Yan, GX Meng, CC Yang… - Journal of Cancer …, 2023 - Springer
Background Tumor vaccines for hepatocellular carcinoma (HCC) is an area of intense
interest. Tremendous clinical trials have been conducted globally, but the efficacy and …
interest. Tremendous clinical trials have been conducted globally, but the efficacy and …
CAR-NK cells in combination therapy against cancer: A potential paradigm
J Li, H Hu, K Lian, D Zhang, P Hu, Z He, Z Zhang… - Heliyon, 2024 - cell.com
Various preclinical and a limited number of clinical studies of CAR-NK cells have shown
promising results: efficient elimination of target cells without side effects similar to CAR-T …
promising results: efficient elimination of target cells without side effects similar to CAR-T …